patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_780622 | REC_0006401 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 20 | 15.1 | 76 | male | 2 | 19 | 5.4 | 5 | osimertinib 80 mg daily | 12.4 | false | MSS | 2026-03-15T05:35:58.425636+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_139584 | REC_0006402 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 27 | 8.6 | 68 | female | 0 | 6 | 4.8 | 3 | pembrolizumab 200 mg q3w | 6.9 | true | MSS | 2026-03-15T05:35:58.425862+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_547026 | REC_0006403 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 22 | 8.6 | 76 | female | 0 | 9 | 4.8 | 5 | sotorasib 960 mg daily | 16.1 | true | MSS | 2026-03-15T05:35:58.426090+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_781237 | REC_0006404 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 22 | 16.5 | 60 | female | 0 | 19 | 4.2 | 1 | alectinib 600 mg BID | 15 | true | MSI-H | 2026-03-15T05:35:58.426325+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_136052 | REC_0006405 | Non-small cell lung cancer | Adenocarcinoma | III | None (PD-L1 high) | 26 | 10.9 | 89 | female | 2 | 18 | 4.4 | 0 | pembrolizumab 200 mg q3w | 22.7 | true | MSI-H | 2026-03-15T05:35:58.426556+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_992888 | REC_0006406 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 19 | 8 | 71 | female | 1 | 8 | 5.2 | 2 | osimertinib 80 mg daily | 10.7 | false | MSS | 2026-03-15T05:35:58.426782+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_403082 | REC_0006407 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 14 | 8.2 | 66 | female | 0 | 71 | 3.8 | 2 | carboplatin + paclitaxel + pembrolizumab | 19.6 | true | MSS | 2026-03-15T05:35:58.427013+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_750484 | REC_0006408 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 19 | 8.3 | 72 | female | 1 | 17 | 5.8 | 1 | osimertinib 80 mg daily | 10.7 | false | MSS | 2026-03-15T05:35:58.427241+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_965378 | REC_0006409 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 29 | 12.7 | 62 | female | 0 | 18 | 6.8 | 2 | alectinib 600 mg BID | 28.6 | true | MSI-H | 2026-03-15T05:35:58.427476+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_128129 | REC_0006410 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 23 | 8.8 | 73 | female | 2 | 12 | 5.2 | 1 | entrectinib 600 mg daily | 18.9 | false | MSS | 2026-03-15T05:35:58.427749+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_478348 | REC_0006411 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 34 | 13.3 | 80 | female | 1 | 15 | 7.8 | 5 | sotorasib 960 mg daily | 7.6 | true | MSI-H | 2026-03-15T05:35:58.427985+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_487330 | REC_0006412 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 24 | 3.9 | 65 | female | 1 | 17 | 5.3 | 2 | pembrolizumab 200 mg q3w | 22 | false | MSS | 2026-03-15T05:35:58.428244+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_322713 | REC_0006413 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 23 | 12 | 60 | male | 1 | 22 | 3.3 | 1 | sotorasib 960 mg daily | 19.2 | false | MSS | 2026-03-15T05:35:58.428485+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_248057 | REC_0006414 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 24 | 11 | 84 | female | 1 | 25 | 6.5 | 0 | entrectinib 600 mg daily | 37.6 | true | MSS | 2026-03-15T05:35:58.428716+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_678068 | REC_0006415 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 28 | 8.7 | 66 | female | 1 | 62 | 4.8 | 4 | pembrolizumab 200 mg q3w | 11 | true | MSS | 2026-03-15T05:35:58.428946+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_103552 | REC_0006416 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 35 | 10.9 | 55 | male | 1 | 15 | 5.5 | 2 | entrectinib 600 mg daily | 14.1 | true | MSS | 2026-03-15T05:35:58.429178+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_945906 | REC_0006417 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 19 | 16.9 | 64 | female | 0 | 18 | 5.6 | 0 | entrectinib 600 mg daily | 39.3 | false | MSI-H | 2026-03-15T05:35:58.429411+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_230434 | REC_0006418 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 30 | 13.9 | 63 | female | 0 | 11 | 5.8 | 4 | entrectinib 600 mg daily | 4 | true | MSI-H | 2026-03-15T05:35:58.429647+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_273894 | REC_0006419 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 30 | 16.7 | 70 | female | 1 | 16 | 7.4 | 7 | sotorasib 960 mg daily | 9.5 | true | MSS | 2026-03-15T05:35:58.429877+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_458420 | REC_0006420 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 7.5 | 67 | female | 1 | 13 | 5.5 | 7 | osimertinib 80 mg daily | 7.5 | true | MSS | 2026-03-15T05:35:58.430102+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_903505 | REC_0006421 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 22 | 11.1 | 90 | female | 1 | 1 | 4.6 | 1 | pembrolizumab 200 mg q3w | 14.8 | true | MSI-H | 2026-03-15T05:35:58.430332+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_548580 | REC_0006422 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 24 | 4.1 | 70 | female | 1 | 24 | 5.3 | 1 | pembrolizumab 200 mg q3w | 28.8 | false | MSS | 2026-03-15T05:35:58.430560+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_881418 | REC_0006423 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 29 | 12.4 | 60 | male | 1 | 18 | 4.4 | 1 | alectinib 600 mg BID | 8.1 | false | MSI-H | 2026-03-15T05:35:58.430844+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_521993 | REC_0006424 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 29 | 9.6 | 74 | female | 2 | 16 | 4.6 | 6 | osimertinib 80 mg daily | 8.6 | false | MSS | 2026-03-15T05:35:58.431075+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_106990 | REC_0006425 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 25 | 14.7 | 87 | female | 1 | 19 | 4.9 | 1 | alectinib 600 mg BID | 12.5 | true | MSS | 2026-03-15T05:35:58.431306+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_827865 | REC_0006426 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 29 | 17.2 | 64 | female | 0 | 15 | 7.3 | 6 | alectinib 600 mg BID | 6 | false | MSS | 2026-03-15T05:35:58.431541+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_106174 | REC_0006427 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 25 | 12.4 | 71 | female | 1 | 23 | 7.2 | 1 | osimertinib 80 mg daily | 15.2 | false | MSI-H | 2026-03-15T05:35:58.431774+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_782602 | REC_0006428 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 11.6 | 68 | female | 1 | 7 | 6.4 | 4 | sotorasib 960 mg daily | 7.8 | true | MSI-H | 2026-03-15T05:35:58.432005+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_795623 | REC_0006429 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 20 | 14.6 | 66 | female | 0 | 20 | 5.7 | 10 | alectinib 600 mg BID | 17.4 | false | MSI-H | 2026-03-15T05:35:58.432265+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_390123 | REC_0006430 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 3.7 | 70 | female | 1 | 40 | 5.4 | 3 | carboplatin + paclitaxel + pembrolizumab | 6.7 | true | MSS | 2026-03-15T05:35:58.432494+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_158652 | REC_0006431 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 18 | 9.3 | 54 | female | 0 | 13 | 6.2 | 8 | pembrolizumab 200 mg q3w | 14.9 | true | MSS | 2026-03-15T05:35:58.432727+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_506809 | REC_0006432 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 18 | 8.8 | 73 | female | 1 | 14 | 6.6 | 1 | entrectinib 600 mg daily | 17.6 | false | MSS | 2026-03-15T05:35:58.432955+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_792476 | REC_0006433 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 21 | 6.7 | 61 | male | 1 | 91 | 6.4 | 5 | carboplatin + paclitaxel + pembrolizumab | 12.5 | false | MSS | 2026-03-15T05:35:58.433186+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_305519 | REC_0006434 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 20 | 13.5 | 72 | male | 2 | 20 | 5.2 | 9 | sotorasib 960 mg daily | 8.8 | false | MSS | 2026-03-15T05:35:58.433421+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_151125 | REC_0006435 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 25 | 10.3 | 54 | female | 0 | 16 | 2.3 | 0 | sotorasib 960 mg daily | 56.8 | false | MSS | 2026-03-15T05:35:58.433654+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_626436 | REC_0006436 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 13.1 | 66 | female | 0 | 16 | 5.8 | 9 | alectinib 600 mg BID | 12 | false | MSS | 2026-03-15T05:35:58.433928+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_420451 | REC_0006437 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 8.6 | 75 | female | 2 | 17 | 6.8 | 4 | osimertinib 80 mg daily | 15.5 | false | MSS | 2026-03-15T05:35:58.434159+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_289573 | REC_0006438 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 26 | 6.8 | 51 | male | 0 | 21 | 6.9 | 5 | pembrolizumab 200 mg q3w | 17.6 | false | MSS | 2026-03-15T05:35:58.434389+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_895711 | REC_0006439 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 27 | 11.6 | 58 | female | 0 | 25 | 6.5 | 3 | osimertinib 80 mg daily | 12.8 | true | MSI-H | 2026-03-15T05:35:58.434626+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_101488 | REC_0006440 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 21 | 14.7 | 73 | female | 1 | 16 | 6.2 | 0 | entrectinib 600 mg daily | 36.1 | true | MSS | 2026-03-15T05:35:58.434856+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_257882 | REC_0006441 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 18 | 5 | 67 | female | 1 | 37 | 5.8 | 6 | carboplatin + paclitaxel + pembrolizumab | 17.3 | false | MSS | 2026-03-15T05:35:58.435085+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_656163 | REC_0006442 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 11.6 | 73 | female | 2 | 19 | 6 | 7 | osimertinib 80 mg daily | 10.1 | false | MSI-H | 2026-03-15T05:35:58.435322+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_864207 | REC_0006443 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 3.9 | 70 | female | 1 | 54 | 6.5 | 4 | carboplatin + paclitaxel + pembrolizumab | 8.4 | false | MSS | 2026-03-15T05:35:58.435549+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_359150 | REC_0006444 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 41 | 20.4 | 58 | male | 0 | 18 | 5.8 | 1 | osimertinib 80 mg daily | 23.1 | false | MSS | 2026-03-15T05:35:58.435787+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_736193 | REC_0006445 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 27 | 6.5 | 70 | male | 2 | 46 | 7.2 | 3 | carboplatin + paclitaxel + pembrolizumab | 18.1 | false | MSS | 2026-03-15T05:35:58.436018+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_224472 | REC_0006446 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 18 | 9.3 | 64 | female | 0 | 21 | 5.6 | 1 | osimertinib 80 mg daily | 14.9 | true | MSS | 2026-03-15T05:35:58.436443+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_677188 | REC_0006447 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 29 | 6.6 | 66 | female | 0 | 5 | 5.9 | 0 | alectinib 600 mg BID | 22 | true | MSS | 2026-03-15T05:35:58.436692+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_141444 | REC_0006448 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 4.2 | 67 | female | 0 | 35 | 6 | 8 | osimertinib 80 mg daily | 8.6 | true | MSS | 2026-03-15T05:35:58.436925+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_886023 | REC_0006449 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 27 | 16.3 | 72 | female | 3 | 13 | 7.6 | 4 | sotorasib 960 mg daily | 16.1 | false | MSI-H | 2026-03-15T05:35:58.437202+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_385799 | REC_0006450 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 26 | 5.9 | 71 | female | 1 | 31 | 4.6 | 1 | pembrolizumab 200 mg q3w | 27.7 | true | MSS | 2026-03-15T05:35:58.437438+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_671714 | REC_0006451 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 20 | 14.8 | 71 | female | 3 | 33 | 5.1 | 1 | pembrolizumab 200 mg q3w | 17.7 | false | MSS | 2026-03-15T05:35:58.437671+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_492273 | REC_0006452 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 35 | 9.9 | 66 | female | 0 | 18 | 5.7 | 6 | entrectinib 600 mg daily | 12.9 | true | MSS | 2026-03-15T05:35:58.437900+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_276037 | REC_0006453 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 28 | 14.2 | 79 | female | 0 | 24 | 3.7 | 0 | alectinib 600 mg BID | 44.4 | true | MSI-H | 2026-03-15T05:35:58.438132+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_807335 | REC_0006454 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 11.9 | 58 | male | 1 | 19 | 2.6 | 8 | osimertinib 80 mg daily | 10.2 | true | MSI-H | 2026-03-15T05:35:58.438366+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_514118 | REC_0006455 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 9.9 | 54 | female | 0 | 14 | 5.3 | 4 | alectinib 600 mg BID | 15.2 | false | MSS | 2026-03-15T05:35:58.438597+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_619241 | REC_0006456 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 20 | 13 | 78 | male | 1 | 17 | 5 | 6 | entrectinib 600 mg daily | 17 | true | MSI-H | 2026-03-15T05:35:58.438835+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_772151 | REC_0006457 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 29 | 6.8 | 71 | male | 2 | 20 | 4.2 | 2 | carboplatin + paclitaxel + pembrolizumab | 11.5 | true | MSS | 2026-03-15T05:35:58.439068+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_552912 | REC_0006458 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 18 | 12.8 | 61 | female | 0 | 9 | 6.5 | 1 | alectinib 600 mg BID | 14.2 | true | MSI-H | 2026-03-15T05:35:58.439307+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_524860 | REC_0006459 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 21 | 14.2 | 68 | female | 0 | 13 | 3.5 | 5 | pembrolizumab 200 mg q3w | 9 | true | MSI-H | 2026-03-15T05:35:58.439542+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_863192 | REC_0006460 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 20 | 10.9 | 66 | female | 0 | 23 | 4.9 | 8 | osimertinib 80 mg daily | 19.6 | false | MSI-H | 2026-03-15T05:35:58.439780+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_533806 | REC_0006461 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 16 | 66 | female | 1 | 8 | 4.8 | 3 | osimertinib 80 mg daily | 4.8 | false | MSI-H | 2026-03-15T05:35:58.440019+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_180111 | REC_0006462 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 28 | 10 | 90 | female | 1 | 23 | 4.8 | 2 | osimertinib 80 mg daily | 20.8 | true | MSS | 2026-03-15T05:35:58.440364+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_970718 | REC_0006463 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 11.3 | 69 | female | 1 | 9 | 5.7 | 5 | sotorasib 960 mg daily | 13.8 | false | MSI-H | 2026-03-15T05:35:58.440609+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_419347 | REC_0006464 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 6.6 | 58 | female | 0 | 1 | 4.7 | 7 | alectinib 600 mg BID | 9.7 | false | MSS | 2026-03-15T05:35:58.440844+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_421633 | REC_0006465 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 30 | 4.8 | 69 | male | 0 | 29 | 6 | 2 | carboplatin + paclitaxel + pembrolizumab | 22.1 | false | MSS | 2026-03-15T05:35:58.441077+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_893575 | REC_0006466 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 4 | 71 | female | 1 | 18 | 5.7 | 4 | osimertinib 80 mg daily | 9.6 | true | MSS | 2026-03-15T05:35:58.441306+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_136664 | REC_0006467 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 15.6 | 56 | male | 0 | 9 | 5.5 | 6 | osimertinib 80 mg daily | 10.6 | true | MSI-H | 2026-03-15T05:35:58.441541+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_567522 | REC_0006468 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 32 | 12.3 | 73 | female | 1 | 17 | 5.8 | 4 | sotorasib 960 mg daily | 13 | true | MSS | 2026-03-15T05:35:58.441772+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_434116 | REC_0006469 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 32 | 11.6 | 63 | male | 1 | 9 | 6.4 | 1 | sotorasib 960 mg daily | 22.8 | false | MSS | 2026-03-15T05:35:58.442007+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_360868 | REC_0006470 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 28 | 9.5 | 65 | female | 1 | 14 | 4.7 | 1 | osimertinib 80 mg daily | 20.6 | false | MSS | 2026-03-15T05:35:58.442241+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_189385 | REC_0006471 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 15 | 5.7 | 73 | female | 1 | 64 | 5 | 7 | carboplatin + paclitaxel + pembrolizumab | 7.7 | false | MSS | 2026-03-15T05:35:58.442475+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_510533 | REC_0006472 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 31 | 5.1 | 66 | female | 1 | 18 | 6 | 2 | pembrolizumab 200 mg q3w | 10.2 | false | MSS | 2026-03-15T05:35:58.442703+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_692749 | REC_0006473 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 19 | 1.5 | 77 | female | 1 | 15 | 6.6 | 2 | entrectinib 600 mg daily | 25.2 | true | MSS | 2026-03-15T05:35:58.442935+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_475113 | REC_0006474 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 22 | 14.7 | 71 | female | 2 | 24 | 4.6 | 2 | entrectinib 600 mg daily | 23.3 | true | MSS | 2026-03-15T05:35:58.443166+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_993566 | REC_0006475 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 22 | 4.1 | 64 | male | 0 | 50 | 6.6 | 2 | carboplatin + paclitaxel + pembrolizumab | 21.1 | false | MSS | 2026-03-15T05:35:58.443467+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_197219 | REC_0006476 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 20 | 6 | 55 | male | 0 | 18 | 8.7 | 5 | pembrolizumab 200 mg q3w | 14.5 | true | MSS | 2026-03-15T05:35:58.443705+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_692494 | REC_0006477 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 20 | 6.7 | 75 | female | 2 | 37 | 6.6 | 4 | pembrolizumab 200 mg q3w | 10.4 | true | MSS | 2026-03-15T05:35:58.444023+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_461640 | REC_0006478 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 8.1 | 71 | female | 1 | 14 | 5.1 | 3 | alectinib 600 mg BID | 9.2 | false | MSS | 2026-03-15T05:35:58.444301+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_107562 | REC_0006479 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 18 | 15.8 | 73 | male | 1 | 16 | 3.5 | 4 | alectinib 600 mg BID | 13.3 | false | MSS | 2026-03-15T05:35:58.444542+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_319432 | REC_0006480 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 20 | 10.3 | 64 | male | 1 | 21 | 4.2 | 3 | alectinib 600 mg BID | 5.2 | false | MSI-H | 2026-03-15T05:35:58.444778+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_346746 | REC_0006481 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 13.2 | 73 | female | 1 | 25 | 5.6 | 7 | osimertinib 80 mg daily | 7.9 | true | MSI-H | 2026-03-15T05:35:58.445010+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_350780 | REC_0006482 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 28 | 8.2 | 70 | female | 2 | 57 | 5.4 | 2 | carboplatin + paclitaxel + pembrolizumab | 22.3 | true | MSS | 2026-03-15T05:35:58.445239+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_184583 | REC_0006483 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 29 | 12.4 | 68 | female | 1 | 15 | 5.3 | 5 | osimertinib 80 mg daily | 12.8 | false | MSI-H | 2026-03-15T05:35:58.445476+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_453842 | REC_0006484 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 35 | 12.1 | 61 | female | 0 | 9 | 5.5 | 5 | sotorasib 960 mg daily | 14.2 | false | MSS | 2026-03-15T05:35:58.445712+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_569196 | REC_0006485 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 27 | 7.8 | 70 | female | 1 | 39 | 5.3 | 3 | carboplatin + paclitaxel + pembrolizumab | 15.7 | true | MSS | 2026-03-15T05:35:58.445939+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_602255 | REC_0006486 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 5.8 | 62 | female | 0 | 43 | 6.1 | 7 | carboplatin + paclitaxel + pembrolizumab | 8.9 | false | MSS | 2026-03-15T05:35:58.446171+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_436943 | REC_0006487 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 20 | 11.2 | 79 | male | 3 | 5 | 4.9 | 5 | entrectinib 600 mg daily | 8.1 | false | MSI-H | 2026-03-15T05:35:58.446407+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_175791 | REC_0006488 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 26 | 3.9 | 61 | female | 0 | 21 | 4 | 1 | pembrolizumab 200 mg q3w | 9.3 | false | MSS | 2026-03-15T05:35:58.446699+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_216227 | REC_0006489 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 21 | 5.5 | 47 | male | 0 | 18 | 4.9 | 1 | osimertinib 80 mg daily | 20.2 | false | MSS | 2026-03-15T05:35:58.446934+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_737664 | REC_0006490 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 22 | 4.5 | 64 | female | 0 | 55 | 5.6 | 4 | pembrolizumab 200 mg q3w | 17.9 | true | MSS | 2026-03-15T05:35:58.447167+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_886399 | REC_0006491 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 15 | 12.3 | 69 | female | 0 | 14 | 7 | 6 | entrectinib 600 mg daily | 12.8 | false | MSI-H | 2026-03-15T05:35:58.447401+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_139551 | REC_0006492 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 28 | 9.6 | 75 | female | 0 | 17 | 5.7 | 2 | sotorasib 960 mg daily | 13.8 | false | MSS | 2026-03-15T05:35:58.447633+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_314830 | REC_0006493 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 15 | 12.4 | 62 | female | 0 | 18 | 6.9 | 5 | osimertinib 80 mg daily | 7.9 | true | MSS | 2026-03-15T05:35:58.447868+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_546147 | REC_0006494 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 30 | 3.7 | 66 | female | 0 | 60 | 7.3 | 4 | carboplatin + paclitaxel + pembrolizumab | 9 | true | MSS | 2026-03-15T05:35:58.448149+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_401568 | REC_0006495 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 15.7 | 68 | male | 0 | 20 | 6.2 | 6 | osimertinib 80 mg daily | 5.4 | true | MSS | 2026-03-15T05:35:58.448395+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_403516 | REC_0006496 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 29 | 5 | 64 | female | 0 | 66 | 4.6 | 2 | carboplatin + paclitaxel + pembrolizumab | 7 | false | MSS | 2026-03-15T05:35:58.448628+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_104202 | REC_0006497 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 20 | 5.4 | 66 | male | 0 | 58 | 7 | 5 | pembrolizumab 200 mg q3w | 4 | false | MSS | 2026-03-15T05:35:58.448862+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_322971 | REC_0006498 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 3.5 | 74 | female | 2 | 37 | 6.6 | 6 | carboplatin + paclitaxel + pembrolizumab | 9.4 | true | MSS | 2026-03-15T05:35:58.449089+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_387880 | REC_0006499 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 8.4 | 69 | female | 1 | 12 | 4.7 | 9 | osimertinib 80 mg daily | 10.1 | false | MSS | 2026-03-15T05:35:58.449318+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_720962 | REC_0006500 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 32 | 17.5 | 74 | male | 3 | 22 | 5.8 | 1 | osimertinib 80 mg daily | 19.5 | true | MSS | 2026-03-15T05:35:58.449562+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.